To systematically explore potential targets in tumor cells that may improve the efficacy of anti–PD-1 therapy, we performed an in vivo CRISPR knockout screen using the MB49 tumor cell line which responds poorly to ICT (22–24) (Fig. 1A). This evidence concerns the gene PDCD1 and neoplasm.